Clinical Trial Update: Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) [Phase 2]

View source ↗

Summary

Phase 2 trial of camrelizumab for recurrent primary central nervous system lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Beijing Sanbo Brain Hospital | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: RECRUITING